We work in partnership with commercial organisations and generate spin-out companies to ensure that innovative approaches and products are implemented into practice.
Our industry partnerships
To ensure that new discoveries deliver patient benefits, we work with industry partners through commercial partnerships, industry-sponsored research and university spin-out companies.
We have expertise in navigating regulatory pathways, particularly for introduction of new areas of technology and in clinical trials. We have a number of highly productive relationships with small and large companies, particularly in the areas of diagnostic development, and vaccine and clinical trials.
The Institute of Infection and Immunity has an impressive record of generating spin-out companies and creating commercial development opportunities from our research, ranging from fundamental scientific discoveries to close-to-clinic applications. These include:
- TiKa Diagnostics Ltd, which is developing compounds to enhance human and veterinary mycobacterial diagnostics
- BUGS Bioscience, which develops microarray-based molecular serotyping for assessing the impact of international vaccine campaigns
- Helperby Therapeutics which is developing new agents to enhance the efficacy of antibiotics for treatment of multi-drug resistant infections.